Skip to main content
Erschienen in: Reactions Weekly 1/2024

01.01.2024 | Case report

Pembrolizumab

Myositis/ myasthenia overlap syndrome and motor axonal polyneuropathy

Erschienen in: Reactions Weekly | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Arman C, et al. Pembrolizumab-induced peripheral nervous system damage: A combination of myositis/ myasthenia overlap syndrome and motor axonal polyneuropathy. Ideggyogyaszati Szemle 76 : 422-426, Nov 2023. Available from: URL: https://dx.doi.org/10.18071/isz.76.0422 [Summarised from an abstract] Arman C, et al. Pembrolizumab-induced peripheral nervous system damage: A combination of myositis/ myasthenia overlap syndrome and motor axonal polyneuropathy. Ideggyogyaszati Szemle 76 : 422-426, Nov 2023. Available from: URL: https://​dx.​doi.​org/​10.​18071/​isz.​76.​0422 [Summarised from an abstract]
Metadaten
Titel
Pembrolizumab
Myositis/ myasthenia overlap syndrome and motor axonal polyneuropathy
Publikationsdatum
01.01.2024
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2024
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-024-52322-z

Weitere Artikel der Ausgabe 1/2024

Reactions Weekly 1/2024 Zur Ausgabe

Case report

Pralsetinib

Case report

Crizotinib